Invesco
SNDX icon

Invesco’s Syndax Pharmaceuticals SNDX Stock Holding History

Invesco’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.02M Sell
138,060
-114,701
-45% -$2.39M ﹤0.01% 2416
2026
Q1 		$5.9M Buy
252,761
+92,236
+57% +$2M ﹤0.01% 2114
2025
Q4 		$3.37M Buy
160,525
+27,434
+21% +$479K ﹤0.01% 2413
2025
Q3 		$2.05M Buy
133,091
+27,934
+27% +$366K ﹤0.01% 2601
2025
Q2 		$985K Buy
105,157
+28,309
+37% +$312K ﹤0.01% 2847
2025
Q1 		$944K Buy
76,848
+25,524
+50% +$360K ﹤0.01% 2858
2024
Q4 		$679K Buy
51,324
+684
+1% +$11.7K ﹤0.01% 3099
2024
Q3 		$975K Buy
50,640
+579
+1% +$12K ﹤0.01% 2915
2024
Q2 		$1.03M Buy
50,061
+1,226
+3% +$25.7K ﹤0.01% 2912
2024
Q1 		$1.16M Buy
48,835
+19,515
+67% +$435K ﹤0.01% 2924
2023
Q4 		$634K Sell
29,320
-7,223
-20% -$111K ﹤0.01% 3098
2023
Q3 		$531K Buy
36,543
+6,095
+20% +$115K ﹤0.01% 3171
2023
Q2 		$637K Sell
30,448
-179,705
-86% -$3.74M ﹤0.01% 3123
2023
Q1 		$4.44M Buy
210,153
+190,006
+943% +$4.73M ﹤0.01% 2276
2022
Q4 		$513K Sell
20,147
-56,244
-74% -$1.31M ﹤0.01% 3252
2022
Q3 		$1.84M Buy
76,391
+53,856
+239% +$1.21M ﹤0.01% 2673
2022
Q2 		$434K Buy
22,535
+4,779
+27% +$79.6K ﹤0.01% 3397
2022
Q1 		$308K Buy
17,756
+148
+0.8% +$2.49K ﹤0.01% 3626
2021
Q4 		$386K Sell
17,608
-2,385
-12% -$44.1K ﹤0.01% 3499
2021
Q3 		$383K Buy
19,993
+2,276
+13% +$37.9K ﹤0.01% 3546
2021
Q2 		$305K Buy
17,717
+8,069
+84% +$148K ﹤0.01% 3625
2021
Q1 		$216K Sell
9,648
-302,815
-97% -$6.84M ﹤0.01% 3662
2020
Q4 		$6.95M Buy
312,463
+247,025
+377% +$5.12M ﹤0.01% 2006
2020
Q3 		$966K Buy
+65,438
New +$997K ﹤0.01% 2835
2020
Q2 		– Sell
-60,152
Closed -$660K – 3683
2020
Q1 		$660K Buy
+60,152
New +$564K ﹤0.01% 2939

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Invesco's SNDX Position: Q2 2026 in Review

Invesco reduced its Syndax Pharmaceuticals (SNDX) stake by 45% in Q2 2026, selling an estimated $2.39M and leaving 138,060 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2416.

Invesco first reported a position in SNDX in Q1 2020 and has held it in 25 quarters since. The position peaked at $6.95M in Q4 2020. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Invesco held 138,060 shares of Syndax Pharmaceuticals worth $3.02M as of Q2 2026.
  • Invesco sold 114,701 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.39M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2416 holding.
  • Invesco first reported a position in Syndax Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Invesco's Syndax Pharmaceuticals position peaked at $6.95M in Q4 2020.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.